Update on Antibody Testing for SARS-CoV-2/ COVID-19

February 2021: Penn Medicine has different serologic tests for SARS-CoV-2 virus that are orderable in Penn Chart. The newest addition to the antibody testing category is a test to measure receptor binding domain (RBD) IgG and RBD IgA antibodies. This post outlines the types of SARS-CoV-2 antibody testing available, when it may be appropriate to order such testing, and how to interpret the results.

Pathology & Laboratory Medicine Update on COVID-19 Testing

Below is the most recent announcement regarding COVID-19 from the Department of Pathology & Laboratory Medicine.

Femtomolar SARS-CoV-2 Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen Burden Quantitation and Tracking

Contributions from our Research Community and from the Department's IDEA Committee

Every single one of us has a crucial role to play, both in fighting the pandemic and for incorporating equity into our teaching, research, and laboratory practice.

Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2

Mark Dittmar, Jae Seung Lee, Kanupriya Whig, Elisha Segrist, Minghua Li, Brinda Kamalia, Lauren Castellana, Kasirajan Ayyanathan, Fabian L Cardenas-Diaz, Edward E Morrisey, Rachel Truitt, Wenli Yan

Penn Medicine Team Uncovers Several Drugs That Could Treat COVID-19

Cell Reports study by Cherry Lab includes promising candidates already approved by FDA such as widely used transplant-rejection drug cyclosporine.